A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE002 (USA) · Dr. Nolan
consented 2022-07-29
AEs
3
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-03-26 (study day 227); relationship: not assessed
moderate
assessed
Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-04-06 (study day 238); relationship: not assessed
moderate
assessed
Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2024-01-09 (study day 516); relationship: N
Data queries
No data queries.